A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.


Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!


WHO Interim Policy Guidance on the Use of Delamanid in the Treatment of MDR-TB in Children and Adolescents


The use of delamanid in the treatment of MDR-TB was recommended by the World Health Organization in 2014. However, these interim policy recommendations were limited to adult MDR-TB patients under very strict conditions. In view of recent data on the use of delamanid in children diagnosed with MDR-TB, the WHO convened an independent, multidisciplinary, international expert panel to assess new data and develop an addendum to the 2014 interim guidance on delamanid, with specific recommendations to paediatric MDR-TB patients.  Based on the assessment of this evidence and recommendations from the expert panel, the WHO now recommends that delamanid may be added to the WHO-recommended longer regimen in children and adolescents (6 – 17 years).

Read the full report here.


Recent News and Announcements

Webinar | The PHOENIx MDR-TB Trial | Thursday, January 19th at 08:30 EST (13:30 CET, 14:30 SAST)

Mark your calendar for Thursday, January 19th from 08:30 to 09:30 EST (13:30-14:30 CET, 14:30-15:30 SAST) for a presentation from Dr. Gavin Churchyard, MBBCh, MMED, FCP (SA), PhD, entitled “Protecting MDR-TB and XDR-TB Affected Households: The PHOENIx MDR-TB Trial”. The Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx) Study, is a phase III trial in development by […]

New: MDR-TB Clinical Trials Landscape Supplement now online

The Pediatric Multidrug Resistant Tuberculosis Clinical Trials Landscape Supplement has been published in the International Journal of Tuberculosis and Lung Disease and is now available online! The supplement can be found in the December 2016 issue of the IJTDL – find a direct link to the issue and all included articles here. A complete list of articles […]

TB Drug Monographs: A Resource to Support the Monitoring and Safe Use of Anti-Tuberculosis Drugs and Second Line Treatment for MDR-TB

This site provides a great resource as a guideline for monitoring for adverse effects during the treatment of MDR-TB.  This guideline is not a treatment guide or a guide for monitoring the progress of treatment.  Advice is based on best available evidence and when this is poor, expert consensus.  These monitoring guidelines were developed in the context of […]

Webinar | The V-QUIN MDR Trial | Thursday, November 3rd at 08:00 EST (13:00 CET)

Update: The link to download Dr. Greg Fox’s presentation can be found here. On Thursday, November 3rd from 08:00 – 09:00 EST (14:00 – 15:00 CET) Dr. Greg Fox hosted a webinar on the V-QUIN MDR Trial. The webinar provided an update on the trial design, start-up, study sites, target population, and anticipated timeline of […]

WHO Target Regimen Profiles for TB Treatment

The development of Target Product Profiles for TB drug regimens (referred as Target Regimen Profiles – TRPs) intends to assist drug regimen developers towards important features and align these with patient and programmatic needs at country level. Link to publication

Event Calendar

Social Media